FIT Plus Calprotectin Improves Young-Onset GI Triage : Gut | May 2026

Introduction

Inflammatory Bowel Disease and early-onset Colorectal Cancer are increasingly encountered in younger adults presenting with lower gastrointestinal symptoms. However, distinguishing inflammatory disease from neoplasia in this age group remains diagnostically challenging.

Problem Statement

The low prevalence of colorectal cancer and higher prevalence of inflammatory bowel disease in younger patients reduce the discriminatory performance of the Faecal Immunochemical Test when used alone. Current pathways risk missed inflammatory disease, delayed referral and inefficient triage.

Summary

This prospective primary-care pilot study evaluated whether combining FIT with Faecal Calprotectin using the York Faecal Calprotectin Care Pathway could improve diagnostic discrimination between colorectal cancer and inflammatory bowel disease in younger adults.

Nearly 900 patients were prospectively enrolled, with a median age of 35 years, representing a clinically important population increasingly seen in both primary care and gastroenterology clinics.

The study demonstrated a major limitation of FIT-only strategies in younger populations. Although FIT showed excellent negative predictive value for the composite endpoint of colorectal cancer or IBD, it failed to identify a substantial proportion of patients with Crohn's Disease.

Importantly, FIT alone missed almost half of Crohn’s disease diagnoses, highlighting the biologic limitation of relying solely on occult bleeding markers in inflammatory bowel disease assessment.

By contrast, combining FIT with the established calprotectin-based pathway achieved detection of all identified colorectal cancer and inflammatory bowel disease cases within the cohort.

The integrated strategy also demonstrated strong discriminatory triage capability, appropriately directing most patients toward either colorectal cancer or inflammatory bowel disease referral pathways.

These findings are clinically significant because diagnostic ambiguity in younger adults frequently leads to delayed IBD diagnosis, repeated consultations and inefficient use of endoscopic resources.

The study additionally addresses a growing epidemiologic challenge: the rising incidence of both early-onset colorectal cancer and inflammatory bowel disease worldwide.

The results reinforce the complementary biologic roles of FIT and calprotectin. FIT primarily reflects mucosal bleeding, whereas calprotectin captures neutrophil-mediated intestinal inflammation, allowing improved differentiation between inflammatory and neoplastic pathology.

Clinically, this combined biomarker strategy may help refine referral pathways in primary care, reducing unnecessary urgent cancer referrals while simultaneously minimizing missed inflammatory bowel disease.

The work is particularly relevant in healthcare systems facing increasing endoscopy demand and diagnostic pathway congestion. Better pre-endoscopic risk stratification could improve resource allocation and reduce diagnostic delay.

The findings also support a broader shift toward multimarker diagnostic algorithms rather than reliance on single stool biomarkers for lower gastrointestinal symptom evaluation.

Importantly, the study demonstrates that biomarker interpretation should be contextualized by patient age and disease prevalence, as diagnostic test performance varies substantially across populations.

Limitations include the pilot nature of the study, relatively low colorectal cancer event numbers and the need for larger validation cohorts before broad implementation.

Future work will likely focus on integrated biomarker-based referral models incorporating FIT, calprotectin, symptom phenotyping and potentially emerging molecular stool biomarkers.

Overall, this study suggests that combining FIT with faecal calprotectin may substantially improve discriminatory referral pathways for younger adults with lower gastrointestinal symptoms, enhancing early detection of both colorectal cancer and inflammatory bowel disease while reducing diagnostic uncertainty.